DOP59: Evaluation of the efficacy of tofacitinib as maintenance therapy in patients with Ulcerative Colitis stratified by OCTAVE Sustain baseline endoscopic subscoreECCO'21 VirtualYear: 2021
Authors: Lee, S.D.(1);Allegretti, J.R.(2);Steinwurz, F.(3);Connelly, S.B.(4);Lawendy, N.(4);Paulissen, J.(5);Gecse, K.B.(6)
(1)Digestive Health Center, University of Washington Medical Center, Seattle- Washington, United States;(2)Division of Gastroenterology- Hepatology and Endoscopy, Brigham and Women’s Hospital, Boston- Massachusetts, United States;(3)Unit of Inflammatory Bowel Disease, Hospital Israelita Albert Einstein, São Paulo, Brazil;(4)Pfizer Inc, Collegeville, Pennsylvania, United States;(5)Pfizer Inc, New York, New York, United States;(6)Amsterdam UMC, Amsterdam, The Netherlands
DOP60: Simplified rules to identify bio-naïve patients with Crohn’s Disease with higher likelihood of clinical remission when initiating vedolizumab versus anti-TNFα therapies: Analysis of EVOLVE study dataECCO'21 VirtualYear: 2021
Authors: Mantzaris, G.(1);Yarur, A.(2);Wang, S.(3);Adsul, S.(4);Kamble, P.(4);Luo, M.(3);Guerin, A.(5);Billmyer, E.(5);Nguyen, H.(5);Bressler, B.(6)
(1)Evangelismos Hospital, Department of Gastroenterology, Athens, Greece;(2)Medical College of Wisconsin, Department of Gastroenterology, Milwaukee, United States;(3)Takeda Pharmaceuticals, Takeda, Cambridge, United States;(4)Takeda Pharmaceuticals-, Takeda, Cambridge, United States;(5)Analysis Group, Analysis Group, Boston, United States;(6)St. Paul’s Hospital, Division of Gastroenterology- Department of Medicine, Vancouver, Canada
DOP61: Impact of prior tumour necrosis factor inhibitor failure and prior corticosteroid use on the maintenance of efficacy of tofacitinib following dose reduction in patients with Ulcerative Colitis who were in stable remission: 6-month data from the double-blind, randomised RIVETING studyECCO'21 VirtualYear: 2021
Authors: Sandborn, W.J.(1);Dubinsky, M.C.(2);Torres, J.(3);Vermeire, S.(4);Kotze, P.G.(5);Su, C.(6);Lawendy, N.(6);Paulissen, J.(7);Mundayat, R.(7);Gardiner, S.(7);Kulisek, N.(6);Modesto, I.(7);D’Haens, G.R.(8)
(1)Division of Gastroenterology, University of California, San Diego- La Jolla- California, United States;(2)Icahn School of Medicine at Mount Sinai, New York, New York, United States;(3)Surgical Department- Gastroenterology Division, Hospital Beatriz Ângelo- Loures, and Faculdade de Medicina- Universidade de Lisboa- Lisbon, Portugal;(4)Department of Gastroenterology and Hepatology, University Hospitals Leuven, Leuven, Belgium;(5)IBD Outpatient Clinics- Colorectal Surgery Unit, Catholic University of Paraná, Curitiba, Brazil;(6)Pfizer Inc, Collegeville, Pennsylvania, United States;(7)Pfizer Inc, New York, New York, United States;(8)Department of Gastroenterology, Amsterdam University Medical Centres, Amsterdam, The Netherlands
DOP62: Immunogenicity to second anti-TNF therapy (IMSAT): Implications for sequencing of biologic therapyECCO'21 VirtualYear: 2021
Authors: Chanchlani, N.(1);Lin, S.(1);Thomas, A.(1);Hamilton, B.(1);Nice, R.(2);Chee, D.(1);Kennedy, N.(1);Goodhand, J.(1);Ahmad, T.(1)
(1)Exeter IBD Pharmacogenetics, Gastroenterology, Exeter, United Kingdom;(2)Exeter Clinical Laboratory International, Biochemistry, Exeter, United Kingdom IMSAT study investigators
DOP63: The Toronto IBD global endoscopic reporting (TIGER) score is well correlated with fecal calprotectin and IBD Disk in Ulcerative Colitis patientsECCO'21 VirtualYear: 2021
Authors: Zittan, E.(1,2);Steinhart, A.H.(3); Aran, H.(1);Milgrom, R.(3); Koifman, E.(1);Gralnek, I.M.(1); Zelber-Sagi, S.(2); Silverberg, M.S.(3)
(1)Emek Medical Center, Ellen and Pinchas Mamber Institute of Gastroenterology and Liver Diseases- IBD Unit, Afula, Israel;(2)University of Haifa, School of Public Health- Faculty of Social Welfare and Health Sciences, Haifa, Israel;(3)Mount Sinai Hospital- Zane Cohen Centre for Digestive Diseases- University of Toronto, Division of Gastroenterology- Department of Medicine, Toronto, Canada
DOP64: Endoscopically injected allogeneic mesenchymal stromal cells alter the mucosal immune cell compartment in patients with ulcerative proctitisECCO'21 VirtualYear: 2021
Authors: Ouboter, L.(1,2);Barnhoorn, M.(2);Plug, L.(2);van Pel, M.(1,3);Zwaginga, J.J.(4);Roelen, D.(1);Pascutti, F.(1);Koning, F.(1);Hawinkels, L.(2);Verspaget, H.(2);van der Meulen - de Jong, A.(2)
(1)Leiden University Medical Center LUMC Building 1, Department of Immunology, Leiden, The Netherlands;(2)Leiden University Medical Center LUMC Building 1, Department of Gastroenterology and Hepatology, Leiden, The Netherlands;(3)Netherlands Center for the Clinical Advancement of Stem Cell & Gene Therapies, Necstgen, Leiden, The Netherlands;(4)Leiden University Medical Center LUMC Building 1, Department of Internal Medicine, Leiden, The Netherlands
DOP65: Dietary therapy with the Crohn’s Disease exclusion diet induces sustained clinical and endoscopic remission in adults with Mild to Moderate Crohn's Disease: Results from the CDED-AD trialECCO'21 VirtualYear: 2021
Authors: Yanai, H.(1,2);Levine , A.(2,3);Hirsch , A.(2,4);Sigall Boneh , R.(2,5);Kopylov , U.(2,6);Banai Eran, H.(1,2); Cohen, N.A.(2,4);Ron, Y.(2,4);Goren , I.(1,2);Leibovitzh, H.(1,2);Wardi , J.(2,7);Zittan, E.(8);Ziv-Baran , T.(2);Abramas, L.(5);Fliss-Isakov , N.(2,4);Raykhel, B.(1);Pfeffer Gik , T.(1,2);Dotan , I.(1,2);Maharshak, N.(2,4)
(1)Rabin Medical Center, IBD center- Division of Gastroenterology, Petah Tikva, Israel;(2)Tel Aviv University, Sackler Faculty of Medicine, Tel Aviv, Israel;(3)Wolfson Medical Center, Paediatric Gastroenterology Unit, Holon, Israel;(4)Tel Aviv Sourasky Medical Center, Department of Gastroenterology and Hepatology, Tel Aviv, Israel;(5)Wolfson Medical Center, Israel PIBD Research Center, Holon, Israel;(6)Sheba Medical Center- Tel Hashomer-, Department of Gastroenterology, Ramat-Gan, Israel;(7)Wolfson Medical Center, Gastroenterology Institute, Holon, Israel;(8)Emek Medical Center, Institute of Gastroenterology and Liver Diseases- IBD unit, Afula, Israel
DOP66: The effect of exclusive enteral nutrition on circulating inflammatory protein levels in paediatric patients with Crohn’s DiseaseECCO'21 VirtualYear: 2021
Authors: Pidoux , M.(1);Logan , M.(1);Milling , S.(2);Ijaz , U.Z.(3);Hansen , R.(4);Russell , R.K.(5);Gerasimidis , K.(1)
(1)University of Glasgow, Department of Human Nutrition, Glasgow, United Kingdom;(2)University of Glasgow, Institute for Infection- Immunity and Inflammation, Glasgow, United Kingdom;(3)University of Glasgow, Civil Engineering- School of Engineering, Glasgow, United Kingdom;(4)Royal Hospital for Children, Department of Paediatric Gastroenterology- Hepatology and Nutrition, Glasgow, United Kingdom;(5)Royal Hospital for Sick Children, Department of Paediatric Gastroenterology- Hepatology and Nutrition, Edinburgh, United Kingdom BINGO Group
DOP67: Comparison of the pharmacokinetics of CT-P13 between Crohn’s Disease and Ulcerative Colitis in biologic-naïve patients; a prospective multi-center observational study of the KASIDECCO'21 VirtualYear: 2021
Authors: Kim, E.S.(1);Park, D.I.(2);Kim, H.J.(3);Lee, Y.J.(4);Koo, J.S.(5);Kim, E.S.(6);Yoon, H.(7);Lee, J.H.(8);Kim, J.W.(9);Shin, S.J.(10);Kim, H.W.(11);Kim, H.S.(12);Park, Y.S.(13);Kim, Y.S.(14);Kim, T.O.(15);Lee, J.(16);Choi, C.H.(17);Han, D.S.(18);Chun, J.(19);Kim, H.S.(20)
(1)Kyungpook National University Hospital, Department of Internal Medicine, Daegu, Korea- Republic Of;(2)Sungkyunkwan University School Of Medicine, Internal Medicine, Seoul, Korea- Republic Of;(3)Kyunghee University School Of Medicine, Internal Medicine, Seoul, Korea- Republic Of;(4)Keimyung University School Of Medicine, Internal Medicine, Daegu, Korea- Republic Of;(5)Korea University College Of Medicine, Internal Medicine, Ansan, Korea- Republic Of;(6)Korea University College Of Medicine, Internal Medicine, Seoul, Korea- Republic Of;(7)Seoul National University College Of Medicine, Internal Medicine, Bundang, Korea- Republic Of;(8)Seoul Song Do Colorectal Hospital, Digestive Endoscopic Center, Seoul, Korea- Republic Of;(9)Seoul National University College Of Medicine, Internal Medicine, Seoul, Korea- Republic Of;(10)Ajou University School Of Medicine, Internal Medicine, Suwon, Korea- Republic Of;(11)Pusan National University School Of Medicine And Medical Research Institute, Internal Medicine, Busan, Korea- Republic Of;(12)Yonsei University Wonju College Of Medicine, Internal Medicine, Wonju, Korea- Republic Of;(13)Eulji University School Of Medicine- Eulji Hospital, Internal Medicine, Seoul, Korea- Republic Of;(14)Inje University College Of Medicine- Seoul Paik Hospital, Internal Medicine, Seoul, Korea- Republic Of;(15)Haeundae Paik Hospital- Inje University College Of Medicine, Internal Medicine, Busan, Korea- Republic Of;(16)Chosun University- School Of Medicine, Internal Medicine, Gwangju, Korea- Republic Of;(17)College Of Medicine- Chung-Ang University, Internal Medicine, Seoul, Korea- Republic Of;(18)Hanyang University College Of Medicine, Internal Medicine, Guri, Korea- Republic Of;(19)Gangnam Severance Hospital- Yonsei University College Of Medicine, Internal Medicine, Seoul, Korea- Republic Of;(20)Chonnam University Medical School, Internal Medicine, Gwangju, Korea- Republic Of; The IBD Research Group of the Korean Association for the Study of Intestinal Diseases
DOP68: Assessment of patients' understanding of Inflammatory Bowel Diseases (IBD): Development and validation of a questionnaire (U-IBDQ)ECCO'21 VirtualYear: 2021
Authors: Ostromohov, G.(1);Fiebelman, M.(1,2);Hirsch, A.(1,3);Ron, Y.(1,3);Aviv Cohen , N.(1,3);Kariv , R.(1,3);Deutsch, L.(1,3);Anbar, R.(1,4);Maharshak, N.(3,5);Fliss Isakov, N.(1,6)
(1)Tel Aviv University, Sackler faculty of medicine, Tel Aviv, Israel;(2)Tel Aviv Medical Center, Department of internal medicine, Tel Aviv, Israel;(3)Tel Aviv Medical Center, IBD Center- Department of Gastroenterology and Liver Diseases, Tel Aviv, Israel;(4)Tel Aviv Medical Center, Nutrition and dietetics department at Tel Aviv Medical center, Tel Aviv, Israel;(5)Tel Aviv University, Tel Aviv, Israel;(6)Tel Aviv Sourasky Medical Center, Department of Gastroenterology and Liver Diseases, Tel Aviv, Israel
DOP69: Ozanimod for induction treatment of Moderate-to-Severe Ulcerative Colitis: Results from a systematic literature review and network meta-analysesECCO'21 VirtualYear: 2021
Authors: Eaton, K.(1);Duperrouzel, C.(1);Bhandari, P.(1);Craigie, S.(1);Bonner, A.(1);Cameron, C.(2);Tencer, T.(3);Kumar, J.(3)
(1)CRG-EVERSANA, Value & Evidence Division- Marketing and Market Access, Ontario, Canada;(2)CRG-EVERSANA, Value & Evidence Division- Marketing and Market Access, Sydney- Nova Scotia, Canada;(3)Bristol Myers Squibb, Global HEOR, Princeton, United States
DOP71: Fungal and bacterial gut microbiota in paediatric onset Inflammatory Bowel Disease introduced to infliximabECCO'21 VirtualYear: 2021
Authors: Ventin-Holmberg, R.(1);Höyhtyä, M.(2);Saqib, S.(3);Korpela, K.(3);Nikkonen, A.(4);Salonen, A.(3);de Vos, W.M.(5);Kolho, K.L.(6)
(1)University of Helsinki, Translational Immunology Research Program, Helsinki, Finland;(2)Tampere University, Faculty of Medicine and Health Technology, Tampere, Finland;(3)University of Helsinki, Human Microbiome Research Program, Helsinki, Finland;(4)Helsinki University Hospital, University of Helsinki and Children´s Hospital, Helsinki, Finland;(5)University of Helsinki- Wageningen University, Human Microbiome Research Program- Laboratory of Microbiology, Helsinki, Finland;(6)University of Helsinki- Helsinki University Hospital, Translational Immunology Research Program- Human Microbiome Research Program- University of Helsinki and Children´s Hospital, Helsinki, Finland
DOP72: Perianal Crohn’s Disease in the biologic era: A population-based cohort studyECCO'21 VirtualYear: 2021
Authors: Jenkinson, P.(1);Plevris, N.(1);Lyons, M.(1);Siakavellas, S.(1);Arnott, I.(1);Jones, G.R.(1);Watson, A.(2);Lees, C.(1)
(1)Edinburgh IBD Unit, Edinburgh IBD Unit, Edinburgh, United Kingdom;(2)Raigmore Hospital, Colorectal Surgery, Inverness, United Kingdom;
DOP73: Antibiotic use differentially affects the risk of antidrug antibody formation during anti-TNFα therapy in Inflammatory Bowel DiseaseECCO'21 VirtualYear: 2021
Authors: Gorelik, Y.(1);Freilich, S.(2);Gerassy-Vainberg, S.(1);Blatt, A.(1);Pressman, S.(1);Focht, G.(3);Friss, C.(3);Loewenberg Weisband, Y.(4);Greenfeld, S.(5);Kariv, R.(5);Ledderman, N.(6);Iris, D.(7);Kashi, Y.(8);Turner, D.(3);Chowers, Y.(1)
(1)Rambam Health Care Campus, Gatroenterology, Haifa, Israel;(2)Rambam Health Care Campus, Gastroenterology, Haifa, Israel;(3)Shaare Zedek Medical Center, Paediatric Gastroenterology, Jerusalem, Israel;(4)Clalit Health Services, Clalit Research Institute- Chief’s Office, Tel Aviv, Israel;(5)Maccabi Healthcare Services, Medical Informatics, Tel Aviv, Israel;(6)Meuhedet Health Services- Tel Aviv- Israel, Medical Manager, Tel Aviv, Israel;(7)Rabin Medical Center, Gastroenterology, Petah Tikva, Israel;(8)Technion Israel Institute of Technology, Faculty of Biotechnology and Food Engineering, Haifa, Israel The Israeli IBD Research Nucleus (IIRN)
DOP74: Initial Clearance of infliximab is a predictor for the time of formation of anti-drug antibodiesECCO'21 VirtualYear: 2021
Authors: Kutschera, M.(1);Primas, C.(1);Reinisch, S.(1);Novacek, G.(1);Kim, S.H.(2);Lee, S.H.(2);Lee , J.H.(2);Reinisch, W.(1);Mould, D.R.(3)
(1)Medical University of Vienna, Department of Gastroenterology and Hepatology, Vienna, Austria;(2)CELLTRION, Inc, Incheon, Korea- Republic Of;(3)Projections Research, Projections Research, Phoenixville, United States
DOP75: Loss-of-response and immunogenicity following immunomodulator withdrawal from anti-tumour necrosis factor alpha combination therapy: Results from a large retrospective cohort studyECCO'21 VirtualYear: 2021
Authors: Mahmoud, R.(1);Schultheiss, J.(1);Louwers, J.(1);van der Kaaij, M.(1);van Hellemondt, B.(1);Mahmmod, N.(2);van Boeckel, P.(2);Jharap, B.(3);Fidder, H.(1);Oldenburg, B.(1)
(1)University Medical Centre Utrecht, Division of Internal Medicine and Dermatology- Department of Gastroenterology and Hepatology, Utrecht, The Netherlands;(2)St. Antonius Hospital, Division of Internal Medicine- Department of Gastroenterology and Hepatology, Nieuwegein, The Netherlands;(3)Meander Medical Center, Division of Internal Medicine- Department of Gastroenterology and Hepatology, Amersfoort, The Netherlands
DOP76: No durable impact of COVID-19 on disease activity and microbiome composition in patients with IBDECCO'21 VirtualYear: 2021
Authors: Funez-dePagnier, G.(1);Lima, S.(1);Duenas-Bianchi, L.(1);Lai, D.(1);Ahmed, W.(1);Battat, R.(1);Scherl, E.(1);Lukin, D.(1);Longman, R.(1)
(1)Weill Cornell Medicine, Medicine, New York, United States
DOP77: Effect of Inflammatory Bowel Disease and Related Medications on COVID-19 Incidence, Disease Severity, and Outcome -The Israeli ExperienceECCO'21 VirtualYear: 2021
Authors: Richter, V.(1);Bermont, A.(1);Cohen, D.L.(1);Broide, E.(1);Shirin, H.(1)
(1)Shamir Medical Center, Gastroenterology, Tzerifin, Israel
DOP78: The differential diagnosis and clinicopathological spectrum of Inflammatory Bowel Disease: An interesting and informative ECCO topical reviewECCO'21 VirtualYear: 2021
Authors: Feakins , R.M.(1); Torres, J.(2); Borralho-Nunes, P.(3,4); Burisch, J.(5); Cúrdia Gonçalves, T.(6,7,8); De Ridder, L.(9); Driessen, A.(10); Lobatón, T.(11); Menchén, L.(12,13,14); Mookhoek, A.(15); Noor, N.(16); Svrcek, M.(17); Villanacci, V.(18); Zidar, N.(19); Tripathi, M.(20)
(1)Department of Cellular Pathology, Royal Free London NHS Trust, London, United Kingdom;(2)Department of Gastroenterology, Hospital Beatriz Ângelo, Loures, Portugal;(3)Department of Pathology, Hospital Cuf Descobertas, Lisbon, Portugal;(4)Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal;(5)Gastrounit, medical division, Hvidovre Hospital, University of Copenhagen, Denmark;(6)Department of Gastroenterology, Hospital da Senhora da Oliveira, Guimarães, Portugal;(7)School of Medicine, University of Minho, Braga/Guimarães, Portugal;(8) ICVS/3B’s–PT Government Associate Laboratory, Braga/Guimarães, Portugal;(9)Department of Paediatric Gastroenterology, Erasmus MC Sophia Children’s Hospital, University Medical Center Rotterdam, The Netherlands;(10)Department of Pathology, University Hospital Antwerp, University Antwerp, Edegem, Belgium;(11)Department of Gastroenterology, Ghent University Hospital, Ghent, Belgium;(12)Department of Digestive System Medicine, Hospital General Universitario-Insitituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain;(13)Department of Medicine, Universidad Complutense, Madrid, Spain;(14)Centro de Investigación Biomédica En Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain;(15)Department of Pathology, Amsterdam UMC, Amsterdam, The Netherlands;(16)Department of Gastroenterology, Addenbrooke's Hospital, Cambridge University Hospitals NHS Trust, Cambridge, United Kingdom;(17)Department of Pathology, Sorbonne Université, AP-HP, Saint-Antoine hospital, Paris, France;(18)Departments of Histopathology, Spedali Civili and University of Brescia, Brescia, Italy;(19)Institute of Pathology, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia;(20)Department of Histopathology, Cambridge Biomedical Campus, Addenbrooke’s Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom; TR Clinicopathological spectrum and differential diagnosis of IBD
